Semaphorin 3A Modulates T Regulatory Cells to Reduce Asthma Inflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current asthma treatments, particularly corticosteroids, come with significant side effects and limited long-term benefits, and there is a need for effective and safe therapeutic approaches as well as reliable biomarkers to assess asthma severity and treatment efficacy.
Innovation Solution
Administration of Semaphorin 3A or its derivatives to patients with asthma, which modulates T regulatory cells by increasing Foxp3 expression, thereby reducing inflammation, and using Semaphorin 3A levels in biological samples to assess asthma severity and treatment efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If inhaled corticosteroids are administered to treat asthma, then asthma symptoms are greatly reduced, but systemic side effects occur including adrenal suppression, decreased bone metabolism, decreased growth in children, and increased susceptibility to infections
Solution Approach 1:
The patent introduces Semaphorin 3A as a mediator substance that acts locally in the airways to reduce inflammation and symptoms. Instead of using corticosteroids that systemically affect the body, Semaphorin 3A serves as an intermediary agent that targets asthma pathology specifically in the respiratory tract through its anti-inflammatory and immunomodulatory properties, thereby achieving symptom control without the harmful systemic side effects of traditional corticosteroid therapy
2Reliability
If continuous daily treatment with corticosteroids is administered, then incidence of asthma symptoms is reduced, but long-term therapeutic benefit in terms of lung function is not achieved and progressive lung changes are not prevented
Solution Approach 1:
The patent utilizes the parameter of Semaphorin 3A concentration and its biological activity to achieve sustained therapeutic effects. By administering Semaphorin 3A at appropriate doses and frequencies, the treatment modifies the inflammatory and immune parameters in the airways, leading to both short-term symptom reduction and long-term preservation of lung function through mechanisms that differ from corticosteroid pathways
3Adaptability or versatility
If alternative therapeutic approaches including leukotriene inhibitors and anti-IgE are used, then treatment options are expanded, but only marginal benefits are shown
Solution Approach 1:
The patent positions Semaphorin 3A as a multi-functional therapeutic agent that can be applied across different asthma phenotypes and severity levels. Unlike alternative therapies that target specific pathways with limited efficacy, Semaphorin 3A exhibits universal anti-inflammatory, immunomodulatory, and tissue-protective effects that provide robust clinical benefits across diverse patient populations, making it a versatile and reliable treatment option
Data Source
AI summary
The present invention relates to methods of treating Asthma using Semaphorin 3A. The invention further relates to assessing Asthma severity or treatment efficacy, comprising determining Semaphorin 3A level in a biological sample of a subject afflicted with Asthma.